May 23, 2018

  • Mr Tucson Dunn to join board of Compumedics as an independent director
  • Mr Dunn’s significant international experience, in particular in China, will strengthen Compumedics board
  • Mr Dunn will provide key and valuable input to Compumedics’ future strategic direction


Compumedics Limited (ASX: CMP) is pleased to announce that its current Board of Directors has unanimously agreed to the appointment of Mr. Tucson Dunn as a Director of the Company, effective immediately, subject to shareholder approval at the Company’s next General Meeting.


Mr. Dunn brings to Compumedics significant international experience in health care delivery, particulalry in senior management roles, including as Hospital CEO, at hospitals in the US, where Mr Dunn is currently based, and at hospitals in Asia, Europe and the Middle East.


Mr Dunn is currently employed by Fosun Group, China’s largest healthcare investment company.


“We are delighted to have Tucson join the Board,’ said Dr. David Burton, Executive Chairman and CEO at Compumedics. ‘He is a seasoned healthcare executive who will bring considerable international experience to the Compumedics Board.’


‘Tucson has extensive experience in health care delivery in markets, which are key to Compumedics on-going future success, including China, other parts of Asia, the US and key markets in Europe and the Middle East.’


‘Tucson joins the board at a very important time with key opportunities not only for the core business but for MEG and also Somfit, the Company’s first consumer sleep device’ said Dr. Burton. ‘Tucson’s contact networks, commercial activation deal focus, and credentials in relation to hospital groups and major deals across the global arena are key traits that can potentially contribute Compumedics value moving forward.’


‘His deep knowledge of healthcare delivery across key international markets, including his current experience with one of China’s largest healthcare investment companies will assist the board and senior management in their strategic growth plans and decision making processes.”


About Compumedics Limited:

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.


Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.


Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.


For further information please contact:

Dr David Burton
Executive Chairman, CEO Executive Director
Ph: + 61 3 8420 7300
Fax: +61 3 8420 7399


 David Lawson
Chief Financial Officer
Ph: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor Relations, Media & PR enquires:


Rod North
Managing Director
Bourse Communications Pty Ltd
Ph: +61 3 9510 8309
Mob: 0408 670 706

Richard Allen
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: 0403 493 049